STEMI再灌注策略五年结局:及时pPCI、延迟pPCI与药物介入策略比较
基于法国FAST-MI注册2005与2010队列中2942例STEMI患者,比较及时pPCI(≤120分钟)、延迟pPCI(>120分钟)与药物介入策略的5年结局。药物介入策略5年生存率(89.8%)高于延迟pPCI(79.5%;校正HR 1.51),与及时pPCI(88.2%;校正HR 1.02)相似。相当比例患者pPCI超出指南推荐时间窗,其5年结局较差。
要点
- 延迟pPCI(>120分钟)5年生存低于药物介入策略
- 药物介入策略与及时pPCI的5年生存相似
- 相当比例STEMI患者pPCI超出推荐时间窗
核心结论
- 延迟pPCI患者5年结局劣于药物介入策略,与指南预期一致。
研究设计与样本
- FAST-MI为法国全国性观察性注册,每5年连续纳入急性心肌梗死患者。
- 分析2005与2010队列中4250例STEMI里接受再灌注且发病至首次呼叫<12小时的2942例。
- 按再灌注策略及pPCI时机分组,采用Cox多变量分析与倾向评分匹配比较5年结局。
主要发现
- 1288例(54%)为及时pPCI(自ECG起≤120分钟),830例(28%)为延迟pPCI(>120分钟),824例(28%)接受静脉纤溶。
- 倾向评分匹配队列及无事件生存分析结果一致。
关键数值与推荐
- 指南推荐:若可在诊断ECG后≤120分钟内实施,pPCI为默认再灌注策略;否则采用药物介入策略。
临床怎么用
- 对无法在ECG后120分钟内完成pPCI的STEMI患者,药物介入策略可能优于延迟pPCI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). METHODS AND RESULTS: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme consists of nationwide observational surveys consecutively recruiting patients admitted for acute myocardial infarction every 5 years. Among the 4250 STEMI patients in the 2005 and 2010 cohorts, those with reperfusion therapy and onset-to-first call time <12 h (n = 2942) were included. Outcomes at 5 years were compared according to type of reperfusion strategy and timing of pPCI, using Cox multivariable analyses and propensity score matching. Among those, 1288 (54%) patients had timely pPCI (≤120 min from ECG), 830 (28%) late pPCI (>120 min), and 824 (28%) intravenous fibrinolysis. Five-year survival was higher with a pharmaco-invasive strategy (89.8%) compared with late pPCI [79.5%; adjusted hazard ratio (HR) 1.51; 1.13-2.02] and similar to timely pPCI (88.2%, adjusted HR 1.02; 0.75-1.38). Concordant results were observed in propensity score-matched cohorts and for event-free survival. CONCLUSION: A substantial proportion of patients have pPCI beyond recommended timelines. As foreseen by the guidelines, these patients have poorer 5-year outcomes, compared with a pharmaco-invasive strategy.
引用
- Danchin N, Popovic B, Puymirat E, et al. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. Eur Heart J. 2020. PMID: 31539043. doi:10.1093/eurheartj/ehz665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。